Caffeine's impact on brain dopamine in Parkinson's patients

A new international study spearheaded by the University of Turku and Turku University Hospital in Finland has revealed significant insights into how high caffeine consumption affects dopamine function in individuals with Parkinson's disease. The study also highlights the potential impact of caffeine intake before undergoing diagnostic brain dopamine imaging.

Background and Previous Research

Earlier studies have consistently shown a link between regular caffeine consumption and a reduced risk of developing Parkinson's disease. However, limited research has been conducted on how caffeine affects disease progression in patients already diagnosed with Parkinson's.

Research Focus and Methodology

The recent study conducted by the University of Turku and Turku University Hospital delved into how long-term caffeine consumption influences brain dopamine function in Parkinson's patients. The research utilized single photon emission computed tomography (SPECT) to measure dopamine transporter (DAT) binding in the brain.

Valtteri Kaasinen, Professor of Neurology at the University of Turku and the principal investigator of the study, highlighted the novelty of their research. "Our study is the first to focus on the effects of caffeine on disease progression and symptoms in relation to dopamine function in Parkinson's disease," he stated.

Clinical Study and Findings

The study compared 163 patients with early-stage Parkinson's disease to 40 healthy controls. For a subset of these participants, examinations and imaging were conducted twice, with an approximately six-year gap between sessions. The researchers assessed changes in brain dopamine transporter binding in relation to the participants' caffeine consumption. This was measured using a validated questionnaire and by analyzing concentrations of caffeine and its metabolites in blood samples.

The study revealed that patients with high caffeine consumption experienced an 8.3-15.4% greater decrease in dopamine transporter binding compared to those with low caffeine consumption. However, this decline in dopamine function is unlikely to be due to a greater reduction in dopamine neurons following caffeine intake. Instead, it is more likely a compensatory mechanism in the brain, similar to what has been observed in healthy individuals after consuming caffeine or other stimulants.

Implications for Symptoms and Imaging

Despite the greater decline in dopamine transporter binding, the study found no evidence that high caffeine intake benefited the symptoms of Parkinson's disease. "While caffeine may offer certain benefits in reducing the risk of Parkinson's disease, our study suggests that high caffeine intake has no benefit on the dopamine systems in already diagnosed patients. It did not result in reduced symptoms of the disease, such as improved motor function," Kaasinen explained.

Another important discovery was that recent caffeine consumption, such as drinking coffee on the morning of an imaging session, temporarily increased DAT binding values. This could complicate the interpretation of brain DAT imaging results, which are commonly used in clinical settings. Based on these findings, the researchers recommend that patients abstain from coffee and caffeine for 24 hours before undergoing diagnostic DAT imaging.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!